Researchers recently profiled the single-cell transcriptomes of thousands of individual parasites to provide the first high-resolution atlas of malaria parasite gene expression across the lifecycle.
New research has discovered a link between dietary zinc intake and protection against Streptococcus pneumoniae, suggesting it aids the immune system.
Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
New research has uncovered that Mycobacterium tuberculosis releases an antacid that remodels phagosomes, preventing immune cells from destroying the bacteria.
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
The first chlamydia vaccine to reach Phase I clinical trials has been observed to be safe and immunogenic in 35 women.
Researchers discover Clostridium difficile is evolving due to genetic changes that allow it to thrive on the Western diet and evade disinfectants making it highly adapted to spread in hospitals.
Coagulation factors, which normally function to clot blood, have been demonstrated to have antibacterial action against Gram-negative bacteria in vitro and in mouse models.
In a study of healthy infants, researchers discover exposure to C. difficile in infancy may provide natural immunization later in childhood.
